Andor Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 34)
Andor Health logo

Andor Health

EmergingHealthTech

Clinical Intelligence

Andor Health uses AI to synthesize patient data into real-time clinical intelligence that streamlines care team communication and coordination across EHR-connected workflows.

AI VisibilityBeta
Overall Score
D34
Category Rank
#584 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
30
Perplexity
36
Gemini
31

About

Andor Health's ThinkAndor platform applies AI to patient data from EHRs, remote monitoring devices, and clinical notes to surface actionable intelligence at the point of care — alerting teams to deteriorating patients, surfacing relevant history during handoffs, and automating documentation that currently requires manual clinical effort. The platform integrates with major EHRs including Epic and Cerner, embedding intelligence into the workflows clinicians already use rather than requiring them to access a separate application.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

34
Overall Score
81
#584
Category Rank
#17
76
AI Consensus
71
stable
Trend
stable
30
ChatGPT
80
36
Perplexity
75
31
Gemini
77
39
Claude
86
37
Grok
85

Key Details

Category
Clinical Intelligence
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Andor Health
Clinical Intelligence

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.